Update: Back to plan A
MorphoSys and Celgene have ended their co-development alliance for MOR202. This has no immediate impact on MOR202's development, and initial data from the Phase I/II in multiple myeloma will be reported at ASCO at the end of May. Meanwhile, MorphoSys is planning a head-to-head study with MOR208 against rituximab in diffuse large B-cell lymphoma (DLBCL). The company had a setback with Roche ending one of two trials with gantenerumab in Alzheimer's disease. We value MorphoSys at €1.76bn.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.